Articles tagged with: Treatment-naive
Headline, News »
On October 8, the Antiviral Drugs Advisory Committee of the Food and Drug Administration (FDA) recommended approval of Selzentry (maraviroc) for use in treatment-naïve patients. The Committee voted 10-4 in favor of extending Selzentry’s use to newly diagnosed individuals, but the FDA has yet to grant official approval.
Selzentry was originally approved for treatment-experienced patients in 2007. Pfizer, Selzentry’s manufacturer, applied for its expanded use in September after receiving results from study 1026.
Study 1026 compared a 300 mg dose of Selzentry given twice daily in combination with Combivir (zidovudine/lamivudine)…